Bilastine-containing pharmaceutical composition and preparing method thereof

A technology for bilastine and preparations, which is applied in the field of pharmaceutical preparations and can solve problems such as patent reports of bilastine pharmaceutical compositions that have not yet been discovered

Inactive Publication Date: 2015-03-11
万全万特制药江苏有限公司
View PDF3 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] No relevant patent report on bilastine p

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bilastine-containing pharmaceutical composition and preparing method thereof
  • Bilastine-containing pharmaceutical composition and preparing method thereof
  • Bilastine-containing pharmaceutical composition and preparing method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0017] Bilastine 10% microcrystalline cellulose 79% Sodium carboxymethyl starch 5% silica 5% Magnesium stearate 1% total 100%

[0018] Preparation Process:

[0019] Mix the prescribed amount of bilastine with microcrystalline cellulose, sodium carboxymethyl starch, silicon dioxide, and magnesium stearate in a mixer. Granulated on a dry formulation machine and then compressed into tablets.

Embodiment 2

[0021] Bilastine 15% microcrystalline cellulose 74% Sodium carboxymethyl starch 0.50% silica 10% Magnesium stearate 1% total 100%

[0022] Preparation Process:

[0023] Mix the prescribed amount of bilastine with microcrystalline cellulose, sodium carboxymethyl starch, silicon dioxide, and magnesium stearate in a mixer. Granulated on a dry formulation machine and then compressed into tablets.

Embodiment 3

[0025] Bilastine 20% microcrystalline cellulose 58% Sodium carboxymethyl starch 0.50% silica 20% Magnesium stearate 1% total 100%

[0026] Preparation Process:

[0027] Mix the prescribed amount of bilastine with microcrystalline cellulose, sodium carboxymethyl starch, silicon dioxide, and magnesium stearate in a mixer. Tablets are compressed by a powder direct compression machine.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the medical technical field, and relates to a bilastine pharmaceutical composition and a preparing method thereof; the preparaiton contains silica, bilastine, a cellulose filling agent, a disintegrant and a lubricant. The invention provides the bilastine oral solid preparation prepared by a non-wet granulation process; the process is simple to operate and suitable for industrialized production; and moreover, the prepared preparation is rapid to disintegrate and high in dissolution efficiency, and improves the bioavailability.

Description

technical field [0001] The invention belongs to the field of pharmaceutical preparations, in particular to oral preparations with good disintegration properties, the preparations include the active ingredient 4-[2-[4-(2-ethoxyethyl)-1H-benzimidazol-2-yl ]-1-piperidinyl]ethyl]-α,α-dimethylphenylacetic acid (bilastine). Background technique [0002] Bilastine 4-[2-[4-(2-ethoxyethyl)-1H-benzimidazol-2-yl]-1-piperidinyl]ethyl]-α,α-dimethyl Phenylacetic acid is the second generation of histamine H developed by Spanish FAES pharmaceutical company 1 Receptor antagonist for the treatment of allergic rhinoconjunctivitis (seasonal and perennial) and urticarial diseases. Studies in healthy subjects and patients with rhinitis have shown that this product is safe, without the sedative effect and cardiotoxicity of commonly used antihistamines. The description of bilastine for treating allergic rhinoconjunctivitis and urticaria diseases is mentioned in CN1290843C. [0003] So far, no r...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/454A61K47/04A61K47/38A61P37/08A61P11/02A61P17/00
CPCA61K47/38A61K9/2059A61K31/454A61K47/32A61K47/36
Inventor 付珊珊刁媛媛马苏峰
Owner 万全万特制药江苏有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap